Roducitabine is an orally available nucleoside antimetabolite that is phosphorylated by uridine cytidine kinase and incorporated into RNA and DNA, inhibiting RNA synthesis and also inhibiting DNA methyltransferase 1. It is studied in solid tumors and metastatic bladder cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
RX-3117, TV-1360
Drug type
Small molecule
Targets
DNA methyltransferase 1 (DNMT1) (secondary target), ribonucleotide reductase (binding partner it blocks)
Mechanism
Cytotoxic, directed at DNA methyltransferase 1 (DNMT1)
Pathways
RNA synthesis inhibition, DNA incorporation and synthesis disruption, pyrimidine-nucleotide salvage pathway, cell cycle arrest, apoptosis
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.